Eugene Schneider, Executive Vice President, Chief Clinical Development Officer, on June 26, 2026, sold 26,000 shares in Ionis Pharmaceuticals (IONS) for $2,107,196. Following the Form 4 filing with the SEC, Schneider has control over a total of 77,114 common shares of the company, with 77,114 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/874015/000087401526000216/xslF345X05/edgardoc.xml
Brian Guan-Chyun Liu, Director, on June 25, 2026, executed a purchase for 371,085 shares in CG Oncology (CGON) for $24,814,454. Following the Form 4 filing with the SEC, Liu has control over a total of 1,886,236 common shares of the company, with 1,886,236 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1991792/000114036126026779/xslF345X05/form4.xml
Jeannette L Knudsen, Chief Legal Officer, on June 26, 2026, sold 4,353 shares in J M Smucker (SJM) for $500,943. Following the Form 4 filing with the SEC, Knudsen has control over a total of 22,034 common shares of the company, with 16,835 shares held directly and 5,199 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/91419/000009141926000069/xslF345X05/wk-form4_1782768569.xml
Sung Lee, Executive Vice President, Chief Financial Officer, on June 29, 2026, sold 3,134 shares in Cytokinetics (CYTK) for $266,390. Following the Form 4 filing with the SEC, Lee has control over a total of 63,221 common shares of the company, with 63,221 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000070/xslF345X05/form4.xml